Primary source: Canada's Drug Agency (CDA-AMC)
CDA-AMC updated PMDE Program procedures to refine evaluation initiation processes and incorporate real-world data for safety reviews and regulatory decisions.
The update alters how MAHs interact with Canadian authorities during post-market safety evaluations and signal assessments, potentially impacting submission timelines and data requirements.
Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.
Regulatory Intelligence Lead
Quarterly
Refines processes for the initiation of evaluations and the use of real-world data to inform safety reviews and regulatory decisions in Canada.
Affects the interaction between MAHs and Canadian health authorities during post-market safety evaluations and signal assessments.
Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.
Canada's Drug Agency (CDA-AMC) updated its Post-Market Drug Evaluation (PMDE) Program, refining processes for initiating evaluations and using real-world data. This affects marketing authorization holders' interaction with Canadian health authorities during post-market safety evaluations and signal assessments.
What changed: CDA-AMC updated PMDE Program procedures to refine evaluation initiation processes and incorporate real-world data for safety reviews and regulatory decisions.
Why it matters: The update alters how MAHs interact with Canadian authorities during post-market safety evaluations and signal assessments, potentially impacting submission timelines and data requirements.
Practical implication: Review updated PMDE Program procedures on CDA-AMC website and assess impact on current post-market surveillance activities in Canada.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
